BUSINESS UPDATE
Arecor Therapeutics plc(“Arecor” or the “Group”) BUSINESS UPDATE Pipeline for future revenue generating partnered collaborations is strong with further deals...
Day: July 14, 2022
Clene Reports Significantly Decreased Mortality in RESCUE-ALS Long-Term Open Label Extension Trial
As of the July 5, 2022, data cutoff, early CNM-Au8® treatment resulted in a significant survival benefit (5 CNM-Au8 deaths...
Tilray Brands to Announce Fourth Quarter and Fiscal Year 2022 Financial Results on July 28, 2022
LEAMINGTON, Ontario, July 14, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray Brands” or the “Company”) (Nasdaq | TSX: TLRY),...
BioAdaptives, Inc. Launching Next Generation Products for Natural Health Practitioners
Enhanced products For Use by Holistic Healthcare Practitioners – $21b US Market For Alternative Medicine Goods and Services LAS VEGAS,...
Theratechnologies Provides Update on the Dose Escalation Portion of Fast Track Designated TH1902 First-in-Human Study in Advanced Resistant Malignancies
Confirmed safety profile at 300 mg/m2 or 1.5 times the therapeutic dose of docetaxel aloneConfirmed low levels of free docetaxel...
Teleflex Announces Second Quarter 2022 Earnings Conference Call Information
WAYNE, Pa., July 14, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second...
InvestmentPitch Media Video Discusses Reliq Health, a Rapidly Growing Global Telemedicine Company, Continues its Growth, Adding 3 New US Contracts and a Significant New Sales Partnership
VANCOUVER, British Columbia, July 14, 2022 (GLOBE NEWSWIRE) -- Reliq Health Technologies Inc. (TSXV:RHT) (OTCPink:RQHTF) (FSE:MHN2), a rapidly growing global...
Mendus AB: Mendus Publishes Preclinical Data Demonstrating Significant Anti-Tumor Synergies of Intratumoral Immune Priming with CTLA-4 Inhibition
Intratumoral injection of allogeneic pro-inflammatory dendritic cells (“ilixadencel”) substantially and sustainably enhanced an otherwise ineffective systemic anti CTLA-4 treatment in...
Press Release: Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis
Dupixent®(dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis First and...
Healthcare Triangle Announces Closing of $6.5 Million Private Placement
PLEASANTON, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- Healthcare Triangle Inc., (Nasdaq: HCTI) (“HCTI” or the “Company”), a leading provider...
Starton Therapeutics Reports Positive Results from Phase 1 Study Evaluating STAR-LLD, Continuous Delivery Lenalidomide
STAR-LLD well tolerated with no dose-related toxicity or adverse eventsSTAR LLD achieved 90% bioavailability across all dosesPlasma levels showed a...
Halberd’s Antibody Effective Against All 4 SARS-CoV-2 Mutations, Including Omicron
Boosts Effectiveness of Commercial Covid Antibodies by 45%Jackson Center, Pennsylvania--(Newsfile Corp. - July 14, 2022) - Halberd Corporation (OTC Pink:...
Build Connections That Drive Change at MEDITECH LIVE
New healthcare summit encourages healthcare leaders to share and shape organizational strategies together CANTON, Mass--(BUSINESS WIRE)--#HealthIT--MEDITECH’s new collaborative leadership event,...
Vivos Therapeutics Announces Multiple Regulatory Clearances in Australia for Its Entire Line of Oral Appliances
Australia clears Vivos technology to treat obstructive sleep apnea for all ages and regardless of severity in broad regulatory win....